To understand why a chemical modification on a stretch of DNA commands such attention, one has to start with the biology. The MGMT gene encodes O6-methylguanine-DNA methyltransferase, a suicide enzyme that patrols the genome and directly reverses a specific type of alkylation damage: the addition of methyl or larger alkyl groups to the O6 position of guanine. This is precisely the lesion created by temozolomide, the backbone chemotherapy drug for glioblastoma, and by nitrosoureas such as lomustine. When the drug damages DNA at O6-methylguanine, MGMT removes the offending adduct and, in the process, consumes itself, sacrificing one protein molecule per repair event. Tumor cells with abundant MGMT are therefore armored against alkylating chemotherapy; they simply undo the damage faster than the drug can inflict it.

The elegant twist is that the MGMT promoter contains a CpG island, a GC-rich region where cytosines can be methylated. When methylation spreads across this promoter, the gene is transcriptionally silenced, and the repair enzyme disappears. Tumor cells lacking MGMT cannot correct O6-alkylguanine lesions, so the damage accumulates, triggers futile cycles of mismatch repair, and culminates in cell death. Methylation of the promoter, in other words, converts temozolomide from a modestly effective drug into a genuinely lethal one for the tumor. The landmark 2005 study by Hegi and colleagues in the New England Journal of Medicine demonstrated this in patients: glioblastoma patients with a methylated MGMT promoter derived clear survival benefit from adding temozolomide to radiotherapy, while those with an unmethylated promoter benefited far less. That finding transformed MGMT promoter methylation from a laboratory curiosity into a decision-making tool used in clinics worldwide.

The predictive logic has since been extended and refined. In elderly patients, where the toxicity of combined chemoradiation is a serious concern, trials such as NOA-08 and the Nordic trial used MGMT methylation to justify temozolomide alone or hypofractionated radiotherapy as alternatives to standard treatment. A 2024 reanalysis of the CE.6 and pooled Nordic/NOA-08 trials by Hegi and colleagues went further, concluding that glioblastomas with a truly unmethylated MGMT promoter derive no benefit from temozolomide at all, a finding that strengthens the case for omitting the drug in that population. Conversely, the CeTeG/NOA-09 trial showed that patients with methylated tumors could safely intensify therapy with a lomustine-temozolomide combination, improving survival. Methylation status also predicts pseudoprogression, the inflammatory radiographic mimic of tumor growth that appears after chemoradiation, and it is now embedded in the RANO 2.0 response assessment criteria that govern how treatment response is judged in trials and clinics.

Yet the review is equally clear that measuring this biomarker is far harder than interpreting it. There is no single gold-standard assay. Methylation-specific PCR, the quantitative real-time version validated by Vlassenbroeck and colleagues, offers speed and sensitivity but interrogates only a handful of CpG sites. Pyrosequencing provides quantitative methylation percentages across selected CpG positions and has met clinical and analytical performance criteria in prospective multicenter validation, but different laboratories target different CpG sites and apply different cutoffs. Genome-wide methylation arrays, now routine in DNA methylation-based tumor classification, can derive MGMT status through algorithms such as MGMT-STP27, allowing methylation calls to be extracted from data already generated for classification purposes. Each method answers a slightly different question about a heterogeneous chemical landscape, and the results do not always agree.

The consequences of this methodological fragmentation are real. An international survey published in Neuro-Oncology Practice asked practitioners whether they truly knew who had a methylated glioma, and the answers revealed widespread uncertainty about assay choice and interpretation. A comprehensive Cochrane-based meta-analysis by Brandner and colleagues confirmed that MGMT testing predicts overall survival in temozolomide-treated glioblastoma patients, but also highlighted how much the accuracy of that prediction depends on the assay used. Tumors with intermediate, so-called gray-zone methylation sit in an interpretive no-man’s-land: partially methylated, they confound binary methylated-or-unmethylated reporting, yet clinical decisions demand a yes-or-no answer. Studies have shown that the number of methylated CpG sites correlates linearly with outcome, suggesting that the dichotomization itself discards meaningful information.

Pre-analytical and biological pitfalls compound the technical ones. Bisulfite conversion, the chemical step underlying most methylation assays, degrades DNA and can lose material unevenly. Intratumoral heterogeneity means a sample from one region of a glioblastoma may not represent the whole. Rare genetic events can masquerade as methylation results: the review’s own authors have reported that homozygous deletion of the MGMT gene, which removes the DNA template entirely, creates a potential pitfall for methylation testing, and other work has described genomic rearrangements of MGMT that contribute to chemotherapy resistance independently of promoter methylation. MGMT expression can also be induced by treatment itself, as xenograft studies demonstrated, meaning a tumor’s initial methylation status may not capture its evolving resistance biology. Immunohistochemistry for the MGMT protein, once hoped to be a simpler surrogate, has been hampered by observer variability and lack of association with survival in validation studies.

The biomarker’s reach now extends well beyond glioblastoma. In IDH-mutant astrocytomas, MGMT methylation contributes to prognostic stratification, although analyses from the CATNON trial program found that the MGMT-STP27 algorithm’s methylation call was not predictive of temozolomide benefit in IDH-mutant anaplastic astrocytomas, complicating the simple predictive story. In 1p/19q-codeleted oligodendrogliomas and in 1p/19q-intact lower-grade gliomas, methylation status associates with survival after alkylating chemotherapy. Emerging data address rare entities such as H3 G34-mutant diffuse hemispheric glioma. A uniform analysis of more than 15,000 nervous system tumors from the Mayo group, cited in the review, is helping map where methylation matters diagnostically and where it is merely passenger biology. The picture that emerges is of a biomarker whose meaning shifts with tumor type, IDH status, and treatment context, demanding increasingly sophisticated interpretation.

Looking forward, the review identifies several converging trajectories. Nanopore sequencing, which reads native DNA and detects methylation directly without bisulfite conversion, has been shown by Halldorsson and colleagues to deliver accurate and comprehensive evaluation of MGMT promoter methylation, potentially eliminating an entire class of pre-analytical artifacts. Droplet digital PCR assays for MGMT methylation are undergoing analytical and clinical validation as more quantitative and robust alternatives to conventional qPCR. Artificial intelligence applied to multiparametric MRI is being trained to predict methylation status noninvasively, using radiomic features from intratumoral and peritumoral imaging, with machine learning models combining imaging and clinical data to distinguish pseudoprogression from true progression. CRISPR-based epigenetic tools, including CRISPRoff and dCas9-mediated silencing, are being used experimentally to manipulate MGMT expression and sensitize tumors to temozolomide, hinting at a future where the biomarker becomes a therapeutic target rather than merely a prognostic readout.

What makes this review resonate beyond the specialist literature is the tension it exposes at the heart of precision oncology. MGMT promoter methylation is simultaneously a triumph, a two-decade-old biomarker that still determines whether thousands of patients receive a drug that can only help them, and a cautionary tale, a test with no standardized method, contested cutoffs, and a gray zone that defies the binary answers clinicians need. Platform trials such as GBM AGILE and the Individualized Screening Trial of Innovative Glioblastoma Therapy now use methylation status to stratify patients toward experimental arms, raising the stakes of every ambiguous result. The Mayo Clinic authors’ verdict is measured but firm: the technical and interpretative challenges are ongoing, yet the biomarker’s clinical value is not in doubt. The task ahead is not to replace MGMT methylation but to tame it, with harmonized assays, quantitative reporting, and technologies that measure the epigenome as it actually exists rather than as a convenient yes-or-no label.

Subject of Research: MGMT promoter methylation as a molecular biomarker for diagnosis and treatment decisions in central nervous system tumors

Article Title: MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions

Article References: MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions. (n.d.). https://doi.org/10.1007/s11060-026-05821-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05821-y

Keywords: MGMT promoter methylation, glioblastoma, temozolomide, DNA methylation, neuro-oncology, biomarker testing, pyrosequencing, methylation-specific PCR, nanopore sequencing, epigenetics, IDH-mutant glioma, pseudoprogression

The chemical tags in question are methyl groups, small molecular attachments that bind to specific positions in the genome called CpG sites, where a cytosine nucleotide sits next to a guanine. DNA methylation is a classic epigenetic mark: it does not change the underlying genetic code, but it can dial gene activity up or down. Because the epigenome responds to environmental stimuli and physiological stress, the researchers reasoned that the massive injury caused by an aneurysm rupture might reshape methylation patterns in ways that influence the biological processes driving DCI, including vascular dysregulation, microthrombosis, cortical spreading depolarizations, and neuroinflammation. Previous candidate-gene studies had pointed to a handful of genes such as INSR, ITPR3, and HAMP, but genome-wide searches had been rare.

The team adopted a two-stage design that has become the gold standard in human genetics. In the discovery stage, they profiled methylation across roughly 450,000 CpG sites using the Illumina Infinium HumanMethylation450 BeadChip in blood samples drawn from 68 aSAH patients within 48 hours of their hemorrhage, before any sign of DCI. This timing matters: by collecting samples before the complication appeared, the investigators ensured that any methylation differences they found could not simply be a consequence of DCI itself. The patients, recruited through the University of Pittsburgh Medical Center Neurovascular Intensive Care Unit, had a mean age of 53.7 years, were predominantly female, and were followed for up to one year to track both DCI occurrence and long-term recovery using the Glasgow Outcome Scale and Modified Rankin Score.

The statistical machinery behind the discovery scan was deliberately rigorous. The researchers applied functional normalization to correct batch effects and technical noise, filtered out probes overlapping common genetic variants, sex chromosomes, and cross-reactive regions, and retained 418,247 CpG sites for analysis. They used M-values, which have more favorable statistical properties than raw beta values, and fitted linear models with empirical Bayes moderation while adjusting for age and sex. Crucially, they also incorporated surrogate variables derived from surrogate variable analysis to absorb the effects of cell-type heterogeneity, a notorious confounder in blood-based methylation studies, since different white blood cell populations carry distinct methylation signatures. The significance threshold for the epigenome-wide scan was set at a stringent 2.4 × 10⁻⁷.

No CpG site crossed that threshold. But the strongest signal in the entire scan landed at a site called cg18031596, annotated to a gene with an obvious biological connection to the disease process: ANGPT1, located on chromosome 8, which encodes angiopoietin-1, a protein central to blood vessel repair and stability. The p-value there was 2.3 × 10⁻⁶, and a post hoc power calculation showed the study had 94.6 percent power to detect a true difference of the observed magnitude. Angiopoietin-1 acts through the Tie2 receptor on endothelial cells, maintaining the integrity of the vascular lining, blocking leakage, and exerting anti-inflammatory effects. In mouse models, overexpression of the protein reduces ischemic lesion volume after arterial occlusion, and earlier clinical work had found that aSAH patients who later developed DCI showed decreased serum levels of angiopoietin-1 early after admission. All of this made ANGPT1 a compelling suspect.

To test the signal properly, the team turned to a replication cohort of 175 additional aSAH patients recruited under identical criteria at the same center. Rather than re-running the full array, they used targeted bisulfite pyrosequencing to measure methylation at five CpG sites across the ANGPT1 locus, including cg18031596 and four neighboring sites. Fifty-eight of the original discovery samples were re-assayed with the same sequencing method, bringing the combined dataset to 233 individuals, of whom 80 developed DCI. The sequencing measurements correlated well with the original array data, with Spearman coefficients ranging from 0.64 to 0.86, and the five targeted CpGs were highly correlated with one another, as expected for sites packed into a single regulatory region.

Then came the twist that gives this study its scientific drama. In the replication cohort, four of the five CpG sites were indeed significantly associated with DCI, passing the Bonferroni-adjusted threshold of 0.045. But the direction of the effects was flipped. In the discovery scan, higher methylation at cg18031596 had appeared to raise DCI risk; in the replication samples, higher methylation was associated with lower risk, with DCI cases showing a mean methylation of 4.84 percent versus 5.56 percent in controls. In the pooled analysis of all 233 patients, three of the five sites remained significant, and the strongest signal, at p = 0.004, came from a CpG that had not even been measured in the original array. By the strict logic of replication, the study failed: a consistent, reproducible effect of ANGPT1 methylation on DCI risk could not be demonstrated.

Rather than burying the inconsistency, the researchers dissected it with unusual transparency. They examined whether smoking, a known driver of methylation changes and a risk factor for aSAH, could explain the flip, but the pattern was messy, with some sites flipping only in smokers and others only in non-smokers. They tested whether the use of surrogate variables in the discovery stage, which could not be replicated in the smaller sequencing dataset, accounted for the discrepancy; this explained the sign reversal at four of the five sites but not at cg18031596 itself. They also noted that the two measurement technologies, array and pyrosequencing, though correlated, were not identical, leaving room for platform-specific artifacts. Finally, they ran a striking simulation: 10,000 random splits of the combined sample into discovery-sized and replication-sized groups. Among the 1,229 simulated discovery sets that produced a significant result, eight showed effect estimates as extreme as the real one, and in every one of those eight, the replication coefficient came out in the opposite direction. In other words, once a small discovery sample stumbles onto a chance extreme result, a direction-flipped replication is almost guaranteed, a phenomenon with a correlation of −0.87 between discovery and replication coefficients in the simulations.

The study also explored whether ANGPT1 methylation might predict recovery rather than DCI itself. In the discovery data, lower methylation at cg18031596 was associated with better Glasgow Outcome Scale scores at three months, with a borderline association at twelve months, and in the sequencing data higher methylation was linked to a lower risk of death at three months. None of these associations replicated cleanly, however, echoing a previous report that high serum angiopoietin-1 predicts better functional outcome. The authors caution that the relationship between methylation and gene expression is tissue-specific and dynamic, and it remains unknown whether methylation at cg18031596 actually regulates ANGPT1 expression in the relevant biological context, though public datasets suggest a correlation in several tissues.

The honest conclusion is that ANGPT1 methylation remains an open question rather than a validated biomarker. The study’s strengths include its longitudinal design, which rules out reverse causality, its careful control of technical artifacts and cell-type heterogeneity, and its willingness to publish a negative and confusing result in full detail, something the field needs more of. Its limitations are equally instructive: small samples inherent to a low-incidence, high-mortality disease, the inability to adjust for methylation quantitative trait loci without genotype data, and the open debate over whether blood is the right tissue for studying brain conditions, even though immune cells in blood do reflect the inflammatory responses implicated in DCI. For now, the message for patients and clinicians is that no epigenetic test can yet predict delayed cerebral ischemia after aneurysm rupture. But the study lays out a clear roadmap: larger, well-powered cohorts with complete genetic and clinical data are needed before ANGPT1, or any methylation marker, can move from statistical curiosity to bedside tool.

Subject of Research: DNA methylation at the ANGPT1 gene as a potential biomarker for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Article Title: ANGPT1 methylation and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients

Article References: Liu, D., Arockiaraj, A. I., Shaffer, J. R., Poloyac, S. M., Sherwood, P. R., Alexander, S. A., Crago, E. A., Weeks, D. E., & Conley, Y. P. (2021). ANGPT1 methylation and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients. Epigenetics Communications, 1(1), Article 3. https://doi.org/10.1186/s43682-021-00001-7

Image Credits: AI Generated

DOI: 10.1186/s43682-021-00001-7

Keywords: aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia, DNA methylation, ANGPT1, epigenome-wide association study, angiopoietin-1, biomarkers, neurocritical care, pyrosequencing, replication failure, surrogate variable analysis, stroke

The biology behind the measurement is central to why this matters. MGMT encodes O6-methylguanine–DNA methyltransferase, a repair enzyme that directly reverses the kind of DNA damage temozolomide inflicts. When the gene’s promoter is silenced by methylation — the addition of methyl groups to CpG dinucleotides in the regulatory region — tumor cells produce little of the repair protein and remain vulnerable to the drug. Methylation of the promoter is therefore a predictive biomarker: patients whose tumors are hypermethylated derive greater benefit from temozolomide, showing improved progression-free and overall survival, while those with unmethylated tumors respond poorly. In the study’s large molecular cohort, tumors classified as hypermethylated at the first time point carried a mean methylation percentage of 35.6 percent, ranging up to 89 percent, whereas unmethylated tumors averaged just 2.1 percent — a wide biological gulf that the binary labels tend to conceal.

To interrogate how that gulf behaves over the course of disease, the researchers, led by Henry Noren and Morana Vojnic of Rutgers Cancer Institute and collaborating institutions, turned to a large commercial molecular profiling database maintained by Caris Life Sciences. They identified patients with recurrent glioma who had undergone molecular testing at two distinct time points and, after excluding cases with insufficient tissue, assembled 426 paired samples. MGMT promoter methylation was assessed by pyrosequencing of CpG sites 74 through 78, following bisulfite conversion of DNA extracted from formalin-fixed paraffin-embedded tissue with at least 50 percent tumor nuclei. The laboratory reported both a quantitative methylation percentage and a categorical status: hypermethylated at 9 percent or above, equivocal between 7 and under 9 percent, and unmethylated below 7 percent. Equivocal cases were assigned to the unmethylated group for analysis, in line with prior studies.

The headline finding is strikingly simple. In 84 percent of tumors — 358 of 426 — the categorical MGMT status was identical at diagnosis and at recurrence, with 52 percent remaining unmethylated and 32 percent remaining hypermethylated. Only 16 percent changed status, and the direction of change was uneven: 11 percent shifted from hypermethylated to unmethylated, while just 5 percent gained hypermethylation. More importantly, when the researchers examined the underlying quantitative values, the average change in methylation percentage across the whole cohort was a modest minus 1.4 percentage points, with a standard deviation of 16.0. Tumors that kept their original classification barely moved at all, drifting by only minus 0.3 points in the consistently unmethylated group and plus 0.6 points in the consistently hypermethylated group. The epigenetic landscape, in other words, is largely frozen between the two surgeries.

The apparent transitions told a different and more instructive story. Tumors that flipped from hypermethylated to unmethylated had baseline methylation levels on average 13.5 percentage points lower than tumors that stayed hypermethylated, a difference that was highly statistically significant. Tumors that gained hypermethylation at recurrence had recurrence values on average 16.3 points lower than consistently hypermethylated tumors. In plain terms, the tumors that changed categories were clustered near the classification thresholds, where a small quantitative shift — whether from intratumoral heterogeneity, differences in sampling, assay variability, or modest epigenetic drift — is enough to move a tumor across the line. The authors conclude that most categorical status changes reflect variability at the margins of classification rather than true epigenetic reprogramming under therapeutic pressure, a distinction with real consequences for how clinicians should read a changed report.

The study also mapped methylation dynamics onto the temporal arc of the disease, using the interval between the two tissue collections as a surrogate for disease course. Among patients whose samples were collected at least three months apart, tumors that remained hypermethylated, lost hypermethylation, or gained hypermethylation all showed longer intervals between samples than tumors that stayed unmethylated. Consistently hypermethylated tumors had intervals 6.7 months longer than consistently unmethylated ones, and tumors that gained hypermethylation showed an 8.2-month difference, with both comparisons reaching statistical significance. The researchers interpret this descriptively: it mirrors the established association between MGMT hypermethylation and better response to alkylating chemotherapy, rather than implying that methylation changes themselves alter the disease trajectory. An exploratory geographic analysis added a curious footnote — frontal lobe tumors were more likely to remain hypermethylated at recurrence, at 41 percent, and less likely to remain unmethylated, at 45 percent, compared with tumors elsewhere in the brain.

To connect the molecular findings to actual clinical behavior, the team analyzed a separate retrospective cohort of 27 adult patients from two academic institutions, Rutgers Cancer Institute and Lenox Hill Hospital, with detailed treatment records. These patients were predominantly diagnosed with glioblastoma, which accounted for 74.1 percent of cases, and nearly all — 96.3 percent — received temozolomide after their initial surgery regardless of MGMT status, consistent with standard of care. At recurrence, 44.4 percent of the cohort was re-treated with the drug. The pattern of who got re-treated tracked the biomarker: temozolomide rechallenge was pursued in 54.5 percent of patients whose tumors remained hypermethylated, compared with 41.7 percent of those whose tumors stayed unmethylated, though the difference did not reach statistical significance in this small sample. Re-irradiation showed the inverse pattern, being more common among patients with consistently unmethylated tumors.

That treatment asymmetry echoes findings from larger clinical trials, including the DIRECTOR trial, which demonstrated that MGMT promoter methylation is a strong predictor of benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma. Retrospective analyses have likewise shown that patients with retained hypermethylation gain more from a second course of the drug, while those with unmethylated tumors are more often directed toward alternative systemic therapies, clinical trials, re-irradiation, or supportive care. What the new study adds is real-world evidence that clinicians are, in fact, weighing MGMT status at recurrence when making these calls — and a quantitative argument that the status they weigh is usually the same one measured months or years earlier at diagnosis.

The implications for laboratory practice may prove to be the study’s most durable contribution. Because binary classification remains the norm in clinical reporting, tumors with borderline methylation — those hovering near the 7 and 9 percent cutoffs — can be labeled in ways that obscure their true position on what is increasingly understood as a quantitative continuum. Prior work has shown that intermediate or low-level methylation is associated with less predictable response to temozolomide and diminished prognostic value compared with clearly unmethylated or robustly hypermethylated tumors. The new data suggest these borderline tumors form a biologically less stable subgroup, vulnerable to reclassification between surgeries for reasons that may have little to do with genuine epigenetic evolution. Routine quantitative reporting, the authors argue, would give oncologists the context needed to interpret a changed status appropriately — and to recognize when a change is more artifact than biology.

The authors are careful to acknowledge the limits of their analysis. Both cohorts were retrospective, introducing potential selection and sampling biases; the interval between surgeries is an imperfect proxy for progression-free survival; the commercial database lacked treatment details, precluding adjustment for therapy-related confounders; and the 27-patient clinical cohort was too small and underpowered for survival analyses, making its findings exploratory. The molecular data also cannot fully disentangle the contributions of intratumoral heterogeneity, sampling variability, and selective pressure from chemotherapy. Still, with one of the largest paired cohorts of recurrent glioma assembled to date and the integration of quantitative methylation percentages alongside categorical labels, the study makes a compelling case that MGMT assessment at diagnosis remains clinically reliable — and that reassessing it at recurrence, with numbers rather than just labels, could sharpen one of the most difficult decisions in brain tumor medicine.

Subject of Research: Stability of MGMT promoter methylation in recurrent glioma and its implications for temozolomide rechallenge

Article Title: Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

Article References: Noren, H., Pelofsky, G., Suffren, B., Mittelman, L., Yohn, C., Twyman, A., Febres-Aldana, C. A., Abramyan, A., Sertil, A., D’Amico, R. S., Sherman, J. H., & Vojnic, M. (2026). Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge. Journal of Neuro-Oncology, 179(3), Article 85. https://doi.org/10.1007/s11060-026-05778-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05778-y

Keywords: glioma, glioblastoma, MGMT promoter methylation, temozolomide, epigenetics, DNA methylation, biomarker, pyrosequencing, recurrent brain tumor, chemotherapy rechallenge, precision oncology, neuro-oncology